Life Biosciences takes a portfolio-of-subsidiaries approach that's structurally different from single-thesis companies like Unity Biotechnology or BioAge Labs. Instead of one research program, it operates as an umbrella over multiple focused biotech subsidiaries, each pursuing a specific aging-related mechanism, including partial cellular reprogramming aimed at neurodegenerative disease and autophagy-based interventions, the cell's internal cleanup process referenced in the Retro Biosciences entry.
This structure lets the company diversify scientific risk: if one subsidiary's mechanism doesn't pan out, the parent company's overall position isn't tied to that single bet. It also means Life Biosciences is better understood as a holding structure with several distinct research theses running in parallel than as a single company with one clear therapeutic story.
The subsidiary model shares some logic with Cambrian Biopharma's holding-company approach, though Life Biosciences keeps its subsidiaries more tightly coordinated around a shared aging-biology thesis rather than acting as a pure funding vehicle for unrelated assets.